Harrow Inc (HROWL)

$24.75

-0.26

(-1.04%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $24.65
    $25.02
    $24.75
    downward going graph

    0.4%

    Downside

    Day's Volatility :1.47%

    Upside

    1.07%

    downward going graph
  • $20.66
    $25.50
    $24.75
    downward going graph

    16.53%

    Downside

    52 Weeks Volatility :18.98%

    Upside

    2.94%

    downward going graph

Returns

PeriodHarrow IncIndex (Russel 2000)
3 Months
1.22%
0.0%
6 Months
3.52%
0.0%
1 Year
1.46%
0.0%
3 Years
-5.06%
-20.2%

Highlights

Market Capitalization
247.5M
Dividend Yield
0.0%
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
0.0%
Return On Equity TTM
44.84%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
Diluted Eps TTM
0.0
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Harrow Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
8
8
Hold
1
1
1
Sell
00
00
00

Company Financials

FY18Y/Y Change
Revenue
41.4M
↑ 54.52%
Net Income
14.6M
↓ 222.03%
Net Profit Margin
35.35%
↑ 80.11%
FY19Y/Y Change
Revenue
51.2M
↑ 23.67%
Net Income
-2.6M
↓ 117.72%
Net Profit Margin
-5.07%
↓ 40.42%
FY20Y/Y Change
Revenue
48.9M
↓ 4.48%
Net Income
-3.4M
↑ 31.91%
Net Profit Margin
-7.0%
↓ 1.93%
FY21Y/Y Change
Revenue
72.5M
↑ 48.3%
Net Income
-18.0M
↑ 426.67%
Net Profit Margin
-24.85%
↓ 17.85%
FY22Y/Y Change
Revenue
88.6M
↑ 22.24%
Net Income
-14.1M
↓ 21.77%
Net Profit Margin
-15.9%
↑ 8.95%
FY23Y/Y Change
Revenue
130.2M
↑ 46.95%
Net Income
-24.4M
↑ 73.3%
Net Profit Margin
-18.75%
↓ 2.85%
Q4 FY22Q/Q Change
Revenue
20.3M
↓ 10.93%
Net Income
1.1M
↓ 116.32%
Net Profit Margin
5.19%
↑ 33.51%
Q1 FY23Q/Q Change
Revenue
26.1M
↑ 28.4%
Net Income
-6.6M
↓ 729.67%
Net Profit Margin
-25.45%
↓ 30.64%
Q2 FY23Q/Q Change
Revenue
33.5M
↑ 28.22%
Net Income
-4.2M
↓ 36.34%
Net Profit Margin
-12.64%
↑ 12.81%
Q3 FY23Q/Q Change
Revenue
34.3M
↑ 2.38%
Net Income
-4.4M
↑ 3.83%
Net Profit Margin
-12.81%
↓ 0.17%
Q4 FY23Q/Q Change
Revenue
36.4M
↑ 6.1%
Net Income
-9.1M
↑ 108.34%
Net Profit Margin
-25.16%
↓ 12.35%
Q1 FY24Q/Q Change
Revenue
34.6M
↓ 4.86%
Net Income
-13.6M
↑ 48.28%
Net Profit Margin
-39.22%
↓ 14.06%
FY18Y/Y Change
Total Assets
49.5M
↑ 106.76%
Total Liabilities
24.7M
↑ 15.95%
FY19Y/Y Change
Total Assets
59.1M
↑ 19.48%
Total Liabilities
31.7M
↑ 28.21%
FY20Y/Y Change
Total Assets
57.5M
↓ 2.73%
Total Liabilities
30.6M
↓ 3.22%
FY21Y/Y Change
Total Assets
98.3M
↑ 71.08%
Total Liabilities
87.4M
↑ 185.19%
FY22Y/Y Change
Total Assets
157.0M
↑ 59.69%
Total Liabilities
130.1M
↑ 48.9%
FY23Y/Y Change
Total Assets
311.8M
↑ 98.54%
Total Liabilities
241.8M
↑ 85.77%
Q4 FY22Q/Q Change
Total Assets
157.0M
↑ 58.62%
Total Liabilities
130.1M
↑ 32.62%
Q1 FY23Q/Q Change
Total Assets
217.5M
↑ 38.51%
Total Liabilities
196.0M
↑ 50.59%
Q2 FY23Q/Q Change
Total Assets
224.0M
↑ 2.98%
Total Liabilities
201.9M
↑ 3.04%
Q3 FY23Q/Q Change
Total Assets
286.1M
↑ 27.71%
Total Liabilities
210.7M
↑ 4.32%
Q4 FY23Q/Q Change
Total Assets
311.8M
↑ 8.98%
Total Liabilities
241.8M
↑ 14.76%
Q1 FY24Q/Q Change
Total Assets
295.1M
↓ 5.35%
Total Liabilities
235.3M
↓ 2.66%
FY18Y/Y Change
Operating Cash Flow
687.0K
↓ 107.8%
Investing Cash Flow
-2.2M
↑ 128.82%
Financing Cash Flow
4.1M
↓ 16.21%
FY19Y/Y Change
Operating Cash Flow
950.0K
↑ 38.28%
Investing Cash Flow
-1.8M
↓ 16.64%
Financing Cash Flow
-1.0M
↓ 124.35%
FY20Y/Y Change
Operating Cash Flow
-1.1M
↓ 215.79%
Investing Cash Flow
-981.0K
↓ 46.48%
Financing Cash Flow
1.4M
↓ 242.45%
FY21Y/Y Change
Operating Cash Flow
5.1M
↓ 562.0%
Investing Cash Flow
-18.7M
↑ 1804.79%
Financing Cash Flow
51.5M
↑ 3491.77%
FY22Y/Y Change
Operating Cash Flow
1.7M
↓ 66.45%
Investing Cash Flow
-1.7M
↓ 90.67%
Financing Cash Flow
54.1M
↑ 5.19%
Q4 FY22Q/Q Change
Operating Cash Flow
-3.7M
↑ 805.37%
Investing Cash Flow
-5.0K
↓ 99.53%
Financing Cash Flow
55.0M
↓ 6210164.21%
Q1 FY23Q/Q Change
Operating Cash Flow
-8.2M
↑ 121.28%
Investing Cash Flow
-131.0M
↑ 2619300.0%
Financing Cash Flow
62.2M
↑ 12.96%
Q2 FY23Q/Q Change
Operating Cash Flow
4.6M
↓ 155.59%
Investing Cash Flow
-1.2M
↓ 99.05%
Financing Cash Flow
189.0K
↓ 99.7%

Technicals Summary

Sell

Neutral

Buy

Harrow Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Harrow Inc
Harrow Inc
-1.49%
3.52%
1.46%
-5.06%
0.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Harrow Inc
Harrow Inc
NA
NA
NA
0.0
0.45
0.0
0.0
NA
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Harrow Inc
Harrow Inc
Buy
$247.5M
0.5%
NA
0.0%

Insights on Harrow Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 36.35M → 34.58M (in $), with an average decrease of 4.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -4.22M → -13.56M (in $), with an average decrease of 53.5% per quarter

Company Information

harrow health, inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the united states. the company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. it also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. its products portfolio includes topical eye drop drug candidates, including surf-100 and surf-200; surf-300, an oral capsule for treating patients suffering from ocular surface diseases, and ded signs and symptoms; klarity drops to protect and rehabilitate the ocular surface pathology for patients with ded; melt-100, a drug that is administered sublingually for conscious sedation during cataract surgery; may-66 that is used for the treatment of symptoms associated with peyronie's diseas

Organization
Harrow Inc
Employees
22
CEO
Industry
Miscellaneous

Discover More

FAQs